SWKH News Alert Swk Hldgs Corp (SWKH) 1.5400 02/15/2015 14:5
Post# of 64074
Posted On: 02/15/2015 3:56:40 PM
Swk Hldgs Corp (SWKH) 1.5400 $SWKH
InsiderInsights.com Daily Round Up 12/5/14: HEES, CCC, CUDA, SC
InsiderInsights - at Seeking Alpha - Sun Dec 07, 2:27AM CST
SC: 22.11 (+0.38), PIH: 7.64 (-0.01), AAP: 150.16 (-1.26), PCI: 20.56 (+0.02), DLR: 68.65 (-2.07), PPR: 5.37 (+0.03), LLY: 70.56 (+0.03), SUNS: 15.79 (-0.05), BMY: 60.04 (+0.56), CCC: 20.15 (+0.28), GV: 2.45 (+0.02), RCL: 75.56 (-1.19), ACE: 113.05 (+0.09), FOX: 33.66 (+0.35), ROC: 79.20 (+0.33), CUDA: 35.68 (-1.14), HEES: 22.94 (+0.77), CO: 4.75 (-0.06), EPE: 12.90 (+0.56)
Tribute Pharmaceuticals Reports Double Digit Revenue Growth in Third Quarter 2014
Marketwire Canada - Mon Nov 10, 1:03PM CST
Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF) (TSX VENTURE:TRX) ("Tribute" or the "Company"
, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the US, today announced financial results for its third quarter ending September 30, 2014. In this press release, all dollar amounts are expressed in Canadian currency - unless otherwise noted - and results are reported in accordance with United States generally accepted accounting principles (U.S. GAAP).
TRX.VN: 0.730 (-0.010), NVS: 102.20 (-0.17)
SWK Holdings Corporation Announces 2014 Third Quarter Financial Results and Equity Financing
GlobeNewswire - Mon Nov 03, 3:01PM CST
-- GAAP net income to SWK stockholders of $0.4 million, or $0.01 per share, and, $3.3 million, or $0.07 per share, for the three and nine month periods ending September 30, 2014, respectively, vs. $0.6 million, or $0.01 per share and $1.1 million, or $0.03 per share, for 2013
SWK Holdings Corporation Establishes Record Date for Rights Offering
GlobeNewswire - Mon Oct 20, 4:44PM CDT
SWK Holdings Corporation (SWKH.OB) ("SWK" or the "Company" , a life science focused specialty finance company, announced that it established a record date for its rights offering. Stockholders of record as of October 30, 2014 will be eligible to participate in the rights offering. As part of the rights offering, holders of shares of common stock will receive non-transferable rights to purchase newly issued shares of common stock of the Company. Each subscription right will entitle stockholders to purchase 0.345662431 shares of common stock of the Company at a subscription price of $0.86 per share. If the rights offering is fully subscribed, the Company expects that the gross proceeds from the rights offering will be approximately $12.5 million. The Company intends to use the proceeds from the rights offering for general corporate purposes.
SWK Holdings Corporation Announces Up to Approximately $115 Million Equity Financing
GlobeNewswire - Mon Aug 18, 4:55PM CDT
SWK Holdings Corporation (SWKH.OB) ("SWK" or the "Company" , a life science focused specialty finance company, announced that on August 18, 2014 that it has entered into a Securities Purchase Agreement (the "Purchase Agreement" and related documents with Carlson Capital, L.P. and affiliates ("Carlson" whereby in a series of transactions funds affiliated with Carlson (the "Stockholder" will purchase new shares in the Company such that its ownership increases to 69.0%.
Response Genetics reports launch of USD12.0m credit facility
M2 - Wed Aug 06, 6:29AM CDT
Molecular diagnostic company Response Genetics (NasdaqCM:RGDX) reported on Tuesday the execution of up to USD12.0m credit agreement with SWK Funding (SWK), a wholly-owned subsidiary of SWK Holdings ( agent).
RGDX: 0.52 (+0.06)
Response Genetics Secures $12.0 Million Credit Facility
GlobeNewswire - Tue Aug 05, 6:08AM CDT
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, and SWK Funding LLC ("SWK" , a wholly-owned subsidiary of SWK Holdings Corporation, as the agent, entered into a credit agreement (the "Credit Agreement" pursuant to which the lenders party thereto provide Response Genetics (the "Company" a term loan in the principal amount up to $12.0 million (the "Loan" .
RGDX: 0.52 (+0.06)
SWK Holdings Corporation Special Committee Responds to Carlson Capital Letter
GlobeNewswire - Mon Jun 23, 10:02AM CDT
The Special Committee of SWK Holdings Corporation (OTCBB:SWKH) ("SWK" or the "Company" , a life science focused specialty finance company, today issued the following statement regarding Carlson Capital's letter to the Special Committee dated June 20, 2014:
InsiderInsights.com Daily Round Up 12/5/14: HEES, CCC, CUDA, SC
InsiderInsights - at Seeking Alpha - Sun Dec 07, 2:27AM CST
SC: 22.11 (+0.38), PIH: 7.64 (-0.01), AAP: 150.16 (-1.26), PCI: 20.56 (+0.02), DLR: 68.65 (-2.07), PPR: 5.37 (+0.03), LLY: 70.56 (+0.03), SUNS: 15.79 (-0.05), BMY: 60.04 (+0.56), CCC: 20.15 (+0.28), GV: 2.45 (+0.02), RCL: 75.56 (-1.19), ACE: 113.05 (+0.09), FOX: 33.66 (+0.35), ROC: 79.20 (+0.33), CUDA: 35.68 (-1.14), HEES: 22.94 (+0.77), CO: 4.75 (-0.06), EPE: 12.90 (+0.56)
Tribute Pharmaceuticals Reports Double Digit Revenue Growth in Third Quarter 2014
Marketwire Canada - Mon Nov 10, 1:03PM CST
Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF) (TSX VENTURE:TRX) ("Tribute" or the "Company"
, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the US, today announced financial results for its third quarter ending September 30, 2014. In this press release, all dollar amounts are expressed in Canadian currency - unless otherwise noted - and results are reported in accordance with United States generally accepted accounting principles (U.S. GAAP). TRX.VN: 0.730 (-0.010), NVS: 102.20 (-0.17)
SWK Holdings Corporation Announces 2014 Third Quarter Financial Results and Equity Financing
GlobeNewswire - Mon Nov 03, 3:01PM CST
-- GAAP net income to SWK stockholders of $0.4 million, or $0.01 per share, and, $3.3 million, or $0.07 per share, for the three and nine month periods ending September 30, 2014, respectively, vs. $0.6 million, or $0.01 per share and $1.1 million, or $0.03 per share, for 2013
SWK Holdings Corporation Establishes Record Date for Rights Offering
GlobeNewswire - Mon Oct 20, 4:44PM CDT
SWK Holdings Corporation (SWKH.OB) ("SWK" or the "Company"
, a life science focused specialty finance company, announced that it established a record date for its rights offering. Stockholders of record as of October 30, 2014 will be eligible to participate in the rights offering. As part of the rights offering, holders of shares of common stock will receive non-transferable rights to purchase newly issued shares of common stock of the Company. Each subscription right will entitle stockholders to purchase 0.345662431 shares of common stock of the Company at a subscription price of $0.86 per share. If the rights offering is fully subscribed, the Company expects that the gross proceeds from the rights offering will be approximately $12.5 million. The Company intends to use the proceeds from the rights offering for general corporate purposes. SWK Holdings Corporation Announces Up to Approximately $115 Million Equity Financing
GlobeNewswire - Mon Aug 18, 4:55PM CDT
SWK Holdings Corporation (SWKH.OB) ("SWK" or the "Company"
, a life science focused specialty finance company, announced that on August 18, 2014 that it has entered into a Securities Purchase Agreement (the "Purchase Agreement" and related documents with Carlson Capital, L.P. and affiliates ("Carlson" whereby in a series of transactions funds affiliated with Carlson (the "Stockholder" will purchase new shares in the Company such that its ownership increases to 69.0%. Response Genetics reports launch of USD12.0m credit facility
M2 - Wed Aug 06, 6:29AM CDT
Molecular diagnostic company Response Genetics (NasdaqCM:RGDX) reported on Tuesday the execution of up to USD12.0m credit agreement with SWK Funding (SWK), a wholly-owned subsidiary of SWK Holdings ( agent).
RGDX: 0.52 (+0.06)
Response Genetics Secures $12.0 Million Credit Facility
GlobeNewswire - Tue Aug 05, 6:08AM CDT
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, and SWK Funding LLC ("SWK"
, a wholly-owned subsidiary of SWK Holdings Corporation, as the agent, entered into a credit agreement (the "Credit Agreement" pursuant to which the lenders party thereto provide Response Genetics (the "Company" a term loan in the principal amount up to $12.0 million (the "Loan" . RGDX: 0.52 (+0.06)
SWK Holdings Corporation Special Committee Responds to Carlson Capital Letter
GlobeNewswire - Mon Jun 23, 10:02AM CDT
The Special Committee of SWK Holdings Corporation (OTCBB:SWKH) ("SWK" or the "Company"
, a life science focused specialty finance company, today issued the following statement regarding Carlson Capital's letter to the Special Committee dated June 20, 2014: 
(0)
(0)Scroll down for more posts ▼